Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA OTCMKTS:CSLLY NYSE:GSK NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.15-3.2%$3.66$1.24▼$4.08$831.21M0.964.16 million shs3.57 million shsCSLLYCSL$88.07+0.2%$82.50$70.22▼$109.00$85.29B0.8281,831 shs18,539 shsGSKGSK$39.11-0.6%$38.50$31.72▼$44.67$79.66B0.515.20 million shs1.86 million shsGSKGSK$39.11-0.6%$38.50$31.72▼$44.67$79.66B0.515.20 million shs1.86 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-4.97%-15.80%+16.07%+125.69%CSLLYCSL0.00%+2.88%+4.82%+11.97%-13.73%GSKGSK0.00%+4.08%+8.32%+3.56%-4.80%GSKGSK0.00%+4.08%+8.32%+3.56%-4.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.9694 of 5 stars3.62.00.04.02.60.80.6CSLLYCSL1.001 of 5 stars0.03.01.70.01.40.01.3GSKGSK2.8565 of 5 stars0.95.02.50.03.90.02.5GSKGSK2.8565 of 5 stars0.95.02.50.03.90.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.75114.63% UpsideCSLLYCSL 4.00Strong BuyN/AN/AGSKGSK 1.88Reduce$37.38-4.42% DownsideGSKGSK 1.88Reduce$37.38-4.42% DownsideCurrent Analyst Ratings BreakdownLatest AKBA, CSLLY, GSK, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M5.21N/AN/A($0.23) per share-13.67CSLLYCSL$14.80B5.76$3.99 per share22.08$20.07 per share4.39GSKGSK$40.10B1.99$5.54 per share7.06$8.07 per share4.85GSKGSK$40.10B1.99$5.54 per share7.06$8.07 per share4.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)CSLLYCSL$2.64BN/A0.0021.531.94N/AN/AN/A8/19/2025 (Estimated)GSKGSK$3.29B$2.1618.108.411.7110.81%49.22%11.31%10/29/2025 (Estimated)GSKGSK$3.29B$2.1618.108.411.7110.81%49.22%11.31%10/29/2025 (Estimated)Latest AKBA, CSLLY, GSK, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$1.201.36%N/AN/AN/AGSKGSK$1.684.30%N/A77.78%N/AGSKGSK$1.684.30%N/A77.78%N/ALatest AKBA, CSLLY, GSK, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20257/31/2025GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84CSLLYCSL0.451.860.85GSKGSK1.070.870.57GSKGSK1.070.870.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CSLLYCSL0.03%GSKGSK15.74%GSKGSK15.74%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CSLLYCSLN/AGSKGSK10.00%GSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableCSLLYCSL32,698968.42 millionN/ANot OptionableGSKGSK68,6292.04 billion1.83 billionOptionableGSKGSK68,6292.04 billion1.83 billionOptionableAKBA, CSLLY, GSK, and GSK HeadlinesRecent News About These CompaniesEthic Inc. Buys 34,185 Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 18 at 6:02 AM | marketbeat.comVestmark Advisory Solutions Inc. Has $4.38 Million Stock Position in GSK PLC Sponsored ADR (NYSE:GSK)August 18 at 5:27 AM | marketbeat.comGSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Citigroup Inc.August 18 at 3:38 AM | marketbeat.comRep. Lisa C. McClain Sells Off Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 18 at 2:01 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKAugust 17 at 11:34 AM | globenewswire.comGSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Brandywine Global Investment Management LLCAugust 17 at 6:54 AM | marketbeat.comNeuberger Berman Group LLC Purchases 19,923 Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 17 at 5:32 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSKAugust 16 at 11:16 AM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSKAugust 16 at 10:00 AM | prnewswire.comFox Run Management L.L.C. Purchases New Position in GSK PLC Sponsored ADR (NYSE:GSK)August 16 at 8:46 AM | marketbeat.comSei Investments Co. Buys 34,395 Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 16 at 8:20 AM | marketbeat.comAtria Wealth Solutions Inc. Has $371,000 Holdings in GSK PLC Sponsored ADR (NYSE:GSK)August 16 at 3:28 AM | marketbeat.comGround Swell Capital LLC Acquires New Stake in GSK PLC Sponsored ADR (NYSE:GSK)August 15 at 7:32 AM | marketbeat.comRussell Investments Group Ltd. Raises Stock Position in GSK PLC Sponsored ADR (NYSE:GSK)August 15 at 6:09 AM | marketbeat.comGSK Egypt’s consolidated net profits shrink to EGP 65m in H1-25August 14, 2025 | zawya.comZGSK Egypt’s consolidated profits fall 29.7% YoY in H1 2025August 14, 2025 | zawya.comZGSK Expands Share Buyback Programme with New PurchaseAugust 14, 2025 | msn.comGSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Mondrian Investment Partners LTDAugust 14, 2025 | marketbeat.comMersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestoneAugust 13, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKAugust 13, 2025 | globenewswire.comCallan Family Office LLC Acquires 9,079 Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, CSLLY, GSK, and GSK Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.14 -0.11 (-3.23%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CSL OTCMKTS:CSLLY$88.07 +0.21 (+0.24%) As of 03:10 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.GSK NYSE:GSK$39.10 -0.26 (-0.65%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.GSK NYSE:GSK$39.10 -0.26 (-0.65%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access